International Journal of Molecular Sciences (Aug 2024)
Role of Extracellular Vesicles in Crohn’s Patients on Adalimumab Who Received COVID-19 Vaccination
- Maria De Luca,
- Biagia Musio,
- Francesco Balestra,
- Valentina Arrè,
- Roberto Negro,
- Nicoletta Depalo,
- Federica Rizzi,
- Rita Mastrogiacomo,
- Giorgia Panzetta,
- Rossella Donghia,
- Pasqua Letizia Pesole,
- Sergio Coletta,
- Emanuele Piccinno,
- Viviana Scalavino,
- Grazia Serino,
- Fatima Maqoud,
- Francesco Russo,
- Antonella Orlando,
- Stefano Todisco,
- Pietro Mastrorilli,
- Maria Lucia Curri,
- Vito Gallo,
- Gianluigi Giannelli,
- Maria Principia Scavo
Affiliations
- Maria De Luca
- Laboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Biagia Musio
- Dipartimento di Ingegneria Civile, Ambientale, del Territorio, Edile e di Chimica, Politecnico di Bari, Via Orabona 4, 70126 Bari, Italy
- Francesco Balestra
- Laboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Valentina Arrè
- Laboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Roberto Negro
- Laboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Nicoletta Depalo
- Institute for Chemical-Physical Processes, Italian National Research Council (IPCF)—CNR SS Bari, Via Orabona 4, 70126 Bari, Italy
- Federica Rizzi
- Institute for Chemical-Physical Processes, Italian National Research Council (IPCF)—CNR SS Bari, Via Orabona 4, 70126 Bari, Italy
- Rita Mastrogiacomo
- Institute for Chemical-Physical Processes, Italian National Research Council (IPCF)—CNR SS Bari, Via Orabona 4, 70126 Bari, Italy
- Giorgia Panzetta
- Laboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Rossella Donghia
- National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Pasqua Letizia Pesole
- Department of Pathology, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Sergio Coletta
- Department of Pathology, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Emanuele Piccinno
- Laboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Viviana Scalavino
- Laboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Grazia Serino
- Laboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Fatima Maqoud
- Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Francesco Russo
- Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Antonella Orlando
- Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Stefano Todisco
- Dipartimento di Ingegneria Civile, Ambientale, del Territorio, Edile e di Chimica, Politecnico di Bari, Via Orabona 4, 70126 Bari, Italy
- Pietro Mastrorilli
- Dipartimento di Ingegneria Civile, Ambientale, del Territorio, Edile e di Chimica, Politecnico di Bari, Via Orabona 4, 70126 Bari, Italy
- Maria Lucia Curri
- Institute for Chemical-Physical Processes, Italian National Research Council (IPCF)—CNR SS Bari, Via Orabona 4, 70126 Bari, Italy
- Vito Gallo
- Dipartimento di Ingegneria Civile, Ambientale, del Territorio, Edile e di Chimica, Politecnico di Bari, Via Orabona 4, 70126 Bari, Italy
- Gianluigi Giannelli
- Scientific Direction, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- Maria Principia Scavo
- Laboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
- DOI
- https://doi.org/10.3390/ijms25168853
- Journal volume & issue
-
Vol. 25,
no. 16
p. 8853
Abstract
Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD) affecting the gastrointestinal tract that can also cause extra-intestinal complications. Following exposure to the mRNA vaccine BNT162b2 (Pfizer-BioNTech) encoding the SARS-CoV-2 Spike (S) protein, some patients experienced a lack of response to the biological drug Adalimumab and a recrudescence of the disease. In CD patients in progression, resistant to considered biological therapy, an abnormal increase in intestinal permeability was observed, more often with a modulated expression of different proteins such as Aquaporin 8 (AQP8) and in tight junctions (e.g., ZO-1, Claudin1, Claudin2, Occludin), especially during disease flares. The aim of this study is to investigate how the SARS-CoV-2 vaccine could interfere with IBD therapy and contribute to disease exacerbation. We investigated the role of the SARS-CoV-2 Spike protein, transported by extracellular vesicles (EVs), and the impact of various EVs components, namely, exosomes (EXOs) and microvesicles (MVs), in modulating the expression of molecules involved in the exacerbation of CD, which remains unknown.
Keywords